M29 Fvc decline over 1 year predicts mortality but not subsequent fvc decline in patients with ipf

M29 Fvc decline over 1 year predicts mortality but not subsequent fvc decline in patients with ipf

IntroductionIn the INPULSIS trials, nintedanib reduced disease progression by reducing FVC decline vs placebo in patients with IPF. Patients who completed an INPULSIS trial could receive open-label nintedanib in the extension trial INPULSIS-ON.AimTo assess the impact of FVC decline in INPULSIS on FV...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thorax 2017-12, Vol.72 (Suppl 3), p.A252
Hauptverfasser: Richeldi, L, Kolb, M, Azuma, A, Stansen, W, Quaresma, M, Stowasser, S, Crestani, B
Format: Artikel
Sprache:eng
Schlagworte:
Mortality
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:IntroductionIn the INPULSIS trials, nintedanib reduced disease progression by reducing FVC decline vs placebo in patients with IPF. Patients who completed an INPULSIS trial could receive open-label nintedanib in the extension trial INPULSIS-ON.AimTo assess the impact of FVC decline in INPULSIS on FVC decline and mortality in INPULSIS-ON.MethodsDescriptive analysis of the proportions of nintedanib-treated patients who had FVC decline
ISSN:0040-6376
1468-3296
DOI:10.1136/thoraxjnl-2017-210983.451